Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis

  • Wang, Huai-Gao (Department of Pathophysiology, Guangdong Medical College) ;
  • Wu, Qing-Yun (Department of Pharmacology, Guangdong Medical College) ;
  • Zhou, Hui (Department of otolaryngology, Affiliated Hospital of Guangdong Medical College) ;
  • Peng, Xin-Sheng (Department of Pharmacology, Guangdong Medical College) ;
  • Shi, Meng-Jie (Department of Pathophysiology, Guangdong Medical College) ;
  • Li, Jie-Mei (Department of Pathophysiology, Guangdong Medical College) ;
  • Zhou, Yan-Fang (Department of Pathophysiology, Guangdong Medical College)
  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Published studies have evaluated associations between the MDM2 SNP309T>G polymorphism and bladder cancer susceptibility. However, these generated inconsistent results. The aim of the present investigation was to quantify the strength of association between MDM2 SNP309T>G polymorphism and bladder cancer risk by conducting a meta-analysis. We searched PubMed and Embase for related studies that had been published in English before April 1, 2014 and associations were assessed by summarizing the odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). Five case-control studies with a total of 972 cases and 1,012 controls were finally identified to be eligible for the meta-analysis. Overall, the results indicated that there was no significant association between the MDM2 SNP309T>G polymorphism and bladder cancer risk (for the allele model G vs. T: OR=1.08, 95% CI 0.85-1.36, p=0.54; for the co-dominant model GG vs. TT: OR=1.20, 95% CI 0.74-1.93, p=0.46; for the dominant model GG+GT vs. TT: OR=0.98, 95% CI 0.80-1.20, p=0.83; for the recessive model GG vs. GT+TT: OR=1.20, 95% CI 0.83-1.74, p=0.33). However, on subgroup analysis by ethnicity, significant associations were found in Caucasians in three models (for the allele model G vs. T: OR=1.41, 95% CI 1.10-1.81, p=0.006; for the co-dominant model GG vs. TT: OR=2.16, 95% CI 1.28-3.63, p=0.004; for the recessive model GG vs. GT+TT: OR=2.06, 95% CI 1.31-3.22, p=0.002). In summary, the present meta-analysis provides evidence that the genotype for the MDM2 SNP309T>G polymorphism may be associated with genetic susceptibility to bladder cancer among Caucasians.

Keywords

References

  1. Cao X, Zhang T, Zhao Z, et al (2012). MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol, 31, 355-9. https://doi.org/10.1089/dna.2011.1338
  2. Fang Z, Chen F, Wang X, et al (2013). XRCC1 Arg194Trp and Arg280His polymorphisms increase bladder cancer risk in Asian population: evidence from a meta-analysis. PLoS One, 8, e64001. https://doi.org/10.1371/journal.pone.0064001
  3. Gangwar R, Mittal RD (2010). Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol, 29, 349-56. https://doi.org/10.1089/dna.2009.0982
  4. GLOBOCAN 2012, IARC. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
  5. Greenblatt MS, Bennett WP, Hollstein M, et al (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78.
  6. Hitzenbichler F, Stoehr CG, Rogenhofer M, et al (2014). Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer. Pathobiology, 81, 53-9. https://doi.org/10.1159/000355976
  7. Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55.
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  9. Knowles MA (2008). Molecular pathogenesis of bladder cancer. Int J Clin Oncol, 13, 287-97. https://doi.org/10.1007/s10147-008-0812-0
  10. Kubbutat MH, Jones SN, Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303. https://doi.org/10.1038/387299a0
  11. Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6. https://doi.org/10.1038/351453a0
  12. Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. https://doi.org/10.7314/APJCP.2012.13.6.2841
  13. Ma Y, Bian J, Cao H (2013). MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PloS One, 8, 56918. https://doi.org/10.1371/journal.pone.0056918
  14. McConkey DJ, Lee S, Choi W, et al (2010). Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol, 28, 429-40. https://doi.org/10.1016/j.urolonc.2010.04.008
  15. Mommsen S, Aagaard J (1983). Tobacco as a risk factor in bladder cancer. Carcinogenesis, 4, 335-8. https://doi.org/10.1093/carcin/4.3.335
  16. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 25, 285-95. https://doi.org/10.1007/s00345-007-0168-5
  17. Olfert SM, Felknor SA, Delclos GL (2006). An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J, 99, 1256-63. https://doi.org/10.1097/01.smj.0000247266.10393.72
  18. Onat OE, Tez M, Ozcelik T, et al (2006). MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 26, 3473-5.
  19. Pietsch EC, Humbey O, Murphy ME (2006). Polymorphisms in the p53 pathway. Oncogene, 25, 1602-11. https://doi.org/10.1038/sj.onc.1209367
  20. Tian X, Tian Y, Ma P, et al (2013). Association between MDM2 SNP309 T>G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 1925-9. https://doi.org/10.7314/APJCP.2013.14.3.1925
  21. Wang L, Liu Z, Jing P, et al (2014). Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol, 35, 1649-52. https://doi.org/10.1007/s13277-013-1227-8
  22. Wang LH, Wang X, Xu WT, et al (2014). MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol, 35, 3167-70. https://doi.org/10.1007/s13277-013-1413-8
  23. Wang M, Zhang Z, Zhu H, et al (2008). A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res, 14, 3633-40. https://doi.org/10.1158/1078-0432.CCR-07-5155
  24. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
  25. Zhao E, Cui D, Yuan L, et al (2012). MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 3471-7. https://doi.org/10.1007/s11033-011-1119-1